Indinavir-13C4,15N

Indinavir-13C4,15N (MK-639 (free base) -13C4,15N) is 13C and 15N labeled Indinavir. Indinavir (MK-639 free base) is an orally active and selective HIV-1 protease inhibitor with a Ki of 0.54 nM for PR. Indinavir exhibits anticancer activity by inhibiting the activation of MMPs-2 hydrolysis, anti-angiogenesis and inducing apoptosis. Indinavir is also a SARS-CoV 3CLpro inhibitor[1][2][3][4].

MK-639 (free base) -13C4,15N; L-735524 (free base) -13C4,15N

12352211

Apoptosis; HIV; HIV Protease; Isotope-Labeled Compounds; MMP; SARS-CoV

Anti-infection; Apoptosis; Metabolic Enzyme/Protease; Others

COVID-19-anti-virus

Inflammation/Immunology; Cancer

O=C([C@H]1N(C[C@@H](O)C[C@@H](CC2=CC=CC=C2)C(N[C@@H]3[C@H](O)CC4=C3C=CC=C4)=O)CCN([13CH2][13C]5=CC=[13CH][15N]=[13CH]5)C1)NC(C)(C)C

C32 13C4H47N4 15NO4

618.75

[1]Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53 (2) :211-216.|[2]Chavan S, et al. The HIV protease inhibitor Indinavir inhibits cell-cycle progression in vitro in lymphocytes of HIV-infected and uninfected individuals. Blood. 2001 Jul 15;98 (2) :383-9.|[3]Esposito V, et al. Evaluation of antitumoral properties of the protease inhibitor indinavir in a murine model of hepatocarcinoma. Clin Cancer Res. 2006 Apr 15;12 (8) :2634-9.|[4]Liu F, et al. Kinetic, stability, and structural changes in high-resolution crystal structures of HIV-1 protease with drug-resistant mutations L24I, I50V, and G73S. J Mol Biol. 2005 Dec 9;354 (4) :789-800. |[5]Hall DC Jr, et al. A search for medications to treat COVID-19 via in silico molecular docking models of the SARS-CoV-2 spike glycoprotein and 3CL protease. Travel Med Infect Dis. 2020 May-Jun;35:101646.

Room temperature

http://file.medchemexpress.com/batch_PDF/HY-B0689S1/

Isotope-Labeled Compounds

No Development Reported